Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case

Shimada, Hideaki; Nagata, Michio; Cho, Akihiro; Takiguchi, Nobuhiro; Kainuma, Osamu; Soda, Hiroaki; Ikeda, Atsushi; Nabeya, Yoshihiro; Yajima, Satoshi; Yamamoto, Hiroshi; Sugiyama, Takahiro; Itami, Makiko

doi:10.1007/s00595-013-0787-y

Cited by 10 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some IgG autoantibodies have been found to respond to tumor-associated antigens in the sera of patients with cancer, even at the early stages (6,7). Since RalA is a tumor antigen, autoantibodies against RalA (s-RalA-Abs) have been reported as potential biomarkers for hepatocellular (8), esophageal (9), colorectal (10), breast (11) and ovarian (12) carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of autoantibodies against Ras‑like GTPases, RalA, in patients with gastric cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Ras-like GTPases, RalA and RalB, are members of the Ras superfamily of small GTPases. RalA expression has been shown to be associated with aggressive clinicopathological characteristics and progression in cancer. RalA protein has been shown to be involved in immune reactions in some patients with cancer; however, the clinicopathological significance of serum RalA antibody in patients with gastric cancer has not been investigated. Serum samples of 291 patients with gastric cancer and 73 healthy controls were analyzed for serum RalA antibody using enzyme-linked immunosorbent assay. A cutoff optical density value was fixed at 0.255 (mean of control + 2 standard deviations). The clinicopathological and prognostic significance of s-RalA-Abs was evaluated. The positivity rate for serum RalA antibody (s-RalA-Abs) was 15%. The presence of serum RalA antibody was higher in younger patients compared with elderly patients, however this tendency was not statistically significant. s-RalA-Abs was not associated with tumor stage. Since s-RalA-Abs was independent of CEA (carcinoembryonic antigen) and carbohydrate antigen 19-9 (CA19-9), the combination of s-RalA-Abs with CEA and CA19-9 significantly increased the detection rate of gastric cancer at each tumor stage. Patients who were tested positive for s-RalA-Abs showed poor long-term survival; however, this association was not statistically significant by multivariate analysis. In conclusion, s-RalA-Abs may be a candidate serum marker for gastric cancer, when used in combination with CEA and/or CA19-9. Additionally, the presence of s-RalA-Abs, in combination with CEA and/or CA19-9, was associated with poor survival in patients with gastric cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of autoantibodies against Ras‑like GTPases, RalA, in patients with gastric cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although there was not enough evidence of s‐p53 Abs in esophageal adenocarcinoma, a few papers have shown that s‐p53 Abs seem to be useful in detecting esophageal adenocarcinoma with p53 overexpression …”

Section: S‐p53 Abs In Patients With Esophageal Squamous Cell Carcinomamentioning

confidence: 99%

p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma

Shimada

2018

Annals of Gastroent Surgery

Self Cite

View full text Add to dashboard Cite

We reviewed our research concerning p53 molecules in esophageal squamous cell carcinoma by focusing on the p53 molecular diagnosis and treatment of esophageal squamous cell carcinoma. First, we developed diagnostic tools to analyze serum p53 autoantibodies to detect esophageal squamous cell carcinoma. Positive rate was around 25% to 30% in all patients and around 20% even in stage I patients. Presence of serum p53 antibodies was significantly associated with overexpression of p53 protein in tumor cells. Seropositive patients were more likely than seronegative patients to be resistant to chemotherapy. Monitoring of the titer of serum p53 autoantibodies was useful in predicting patients at high risk of recurrence and/or treatment response. Second, using Ad5CMV‐p53 for 10 patients with advanced esophageal squamous cell carcinoma, we carried out a phase I/II study of adenoviral‐mediated p53 gene therapy. Although no complete response was observed, local tumor was stabilized in nine patients. No serious adverse events related to Ad5CMV‐p53 were observed in these patients. One patient survived for over 5 years after the start of p53 gene therapy. Intratumoral injection of Ad5CMV‐p53 is therefore safe, feasible, and biologically active when given in multiple doses to patients with esophageal squamous cell carcinoma. Our observations from these clinical studies indicate that p53 is a useful molecular target both in the diagnosis and in the treatment of esophageal squamous cell carcinoma.

show abstract

“…The G 1 check point represents the major machinery for responding to DNA damage and is regulated by the p53/MDM2-p21 pathway, which is capable of inducing sustained and sometimes permanent G 1 arrest (2). The G 1 checkpoint involves two critical tumor suppressors governed by p53 and RB, both of which represent major mechanisms commonly deregulated in many human cancers (3,4).…”

mentioning

confidence: 99%

RFPL4A Increases the G1 Population and Decreases Sensitivity to Chemotherapy in Human Colorectal Cancer Cells

Naito¹,

Yamamoto

Kagawa

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Cell cycle-arrested cancer cells are resistant to conventional chemotherapy. Results: Microarray analyses showed that expression of RFPL4A was significantly up-regulated in these G 1 -retained cells. Conclusion: RFPL4A is a novel factor inducing G 1 retention and reduced sensitivity to chemotherapy. Significance: Combination therapy using RFPL4A inhibition and conventional anti-cancer drugs may represent a promising therapeutic approach for intractable cancer patients.

show abstract

Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case

Cited by 10 publications

References 19 publications

Prevalence of autoantibodies against Ras‑like GTPases, RalA, in patients with gastric cancer

Prevalence of autoantibodies against Ras‑like GTPases, RalA, in patients with gastric cancer

p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma

RFPL4A Increases the G1 Population and Decreases Sensitivity to Chemotherapy in Human Colorectal Cancer Cells

Contact Info

Product

Resources

About